Enclomiphene + HCG for testosterone therapy: the fertility-preserving alternative.

The problem with exogenous testosterone

Testosterone replacement therapy (TRT — Testosterone Replacement Therapy) is effective for symptomatic hypogonadism. The TRAVERSE trial (Lincoff et al., NEJM 2023) confirmed cardiovascular non-inferiority in high-risk men, and symptom data across multiple trials is solid: libido improves, lean mass improves, fatigue and mood often improve in men who are genuinely deficient. The mechanism is not in question.

What is also not in question: exogenous testosterone suppresses the HPG axis completely. When you inject or apply testosterone, the hypothalamus reads supraphysiological androgen levels and shuts off gonadotropin-releasing hormone (GnRH — Gonadotropin-Releasing Hormone) pulse generation. The pituitary stops secreting luteinizing hormone (LH — Luteinizing Hormone) and follicle-stimulating hormone (FSH — Follicle-Stimulating Hormone). Without LH, the Leydig cells in the testes stop producing endogenous testosterone. Without FSH, Sertoli cells stop supporting spermatogenesis. The result is predictable and well-documented: testicular atrophy occurs within months, and azoospermia — the complete absence of sperm — develops in roughly 65–75% of men on TRT within six months. ^[1]

For a 55-year-old with completed fertility, this is a practical non-issue. For a 32-year-old with low testosterone who wants children — now or in the next several years — it is the defining clinical constraint. This is the gap that enclomiphene and HCG (Human Chorionic Gonadotropin) are designed to fill.

The HPG axis, briefly

The hypothalamic-pituitary-gonadal (HPG) axis is a closed-loop feedback system. The hypothalamus releases GnRH in pulses — the pulsatility matters, because continuous GnRH paradoxically downregulates LH, which is why GnRH agonists used in prostate cancer therapy achieve chemical castration rather than stimulation. Those GnRH pulses trigger the anterior pituitary to release LH and FSH. LH acts on testicular Leydig cells, driving cholesterol conversion to testosterone via the steroidogenic pathway — specifically, LH signals through the cyclic AMP (cAMP — cyclic Adenosine Monophosphate) cascade to upregulate StAR (Steroidogenic Acute Regulatory) protein, which is the rate-limiting step in testosterone synthesis. FSH, meanwhile, acts on Sertoli cells to maintain the seminiferous tubule environment that supports sperm development.

Serum testosterone feeds back to both the hypothalamus and pituitary via two routes: direct androgen receptor binding, and aromatization to estradiol (E2 — Estradiol) which has potent negative feedback at the hypothalamic level. This is the loop. Interrupt any node — including by flooding the system with exogenous testosterone — and the upstream signal collapses.

Enclomiphene and HCG work at different nodes of this same axis. Enclomiphene works centrally, at the hypothalamus and pituitary. HCG works peripherally, at the Leydig cell. Understanding this distinction is the pharmacological foundation for everything that follows.

Enclomiphene: what it is, what it signals

Enclomiphene citrate is the trans-isomer of clomiphene citrate — the selective estrogen receptor modulator (SERM — Selective Estrogen Receptor Modulator) that has been used off-label in male hypogonadism and fertility for decades. SERMs work by blocking estrogen receptors in specific tissues, and in the hypothalamus and pituitary, blocking those receptors removes the E2-mediated negative feedback on GnRH and LH/FSH secretion. The HPG axis reads less estradiol signal, interprets this as low testosterone, and increases GnRH pulsatility. LH and FSH rise. Leydig cells receive more LH signal. Endogenous testosterone increases — but the axis remains intact and functional. Spermatogenesis continues.

This is why SERMs were historically used in male infertility: they raise T without suppressing sperm. Enclomiphene's advantage over its parent molecule is the elimination of the cis-isomer — zuclomiphene — which is estrogenic, long-lived (half-life measured in weeks), and responsible for most of the side effects associated with clomiphene use in men: visual disturbances, mood instability, and estradiol-driven side effects that undermine the therapeutic goal. Enclomiphene isolates the antiestrogenic SERM effect without the agonist baggage. ^[2,3]

The pharmacokinetic profile is meaningfully different as a result. Enclomiphene has a half-life of approximately 5–10 hours (published estimates vary by assay and population), allowing once-daily oral dosing with predictable steady-state kinetics. Clomiphene's zuclomiphene component, by contrast, accumulates with each cycle, which is why men on long-term clomiphene often experience worsening estrogenic side effects over time. ^[3]

Clomiphene vs. enclomiphene — the isomer question

Clomiphene citrate (commonly known as Clomid) has been used off-label in men since the 1970s. It works — testosterone rises, LH rises, some fraction of men on it maintain sperm counts — but the signal is messier than enclomiphene's because you are giving two isomers with opposing pharmacological profiles simultaneously. The trans-enclomiphene is antiestrogenic at the hypothalamus and pituitary (the desired effect). The cis-zuclomiphene is estrogenic at peripheral tissues and mildly antiestrogenic centrally — and it lingers.

In men, this creates a ceiling problem: as zuclomiphene accumulates across weeks of treatment, its peripheral estrogenicity partially offsets the HPG signal that enclomiphene is generating. You end up with a less consistent testosterone raise, more estradiol-related side effects (mood swings, water retention, nipple sensitivity), and a pharmacological moving target that is difficult to optimize. Enclomiphene removes this variable. What you get is a clean antiestrogenic signal at the HPG axis — and nothing else. ^[2,3]

Phase 3 data: what Androxal actually showed

The most rigorous enclomiphene data comes from the Androxal Phase 3 program, a series of randomized controlled trials conducted by Repros Therapeutics that compared enclomiphene citrate to placebo and to testosterone gel (AndroGel) in secondary hypogonadal men — men whose low testosterone was due to HPG axis dysregulation rather than primary testicular failure. ^[4,5]

The headline findings across the ZA-304 and ZA-305 trials were consistent:

• Enclomiphene 12.5 mg and 25 mg daily raised morning total testosterone into the normal range (≥300 ng/dL) in a meaningful proportion of men, with mean testosterone levels reaching 400–500 ng/dL at standard doses.
• LH and FSH rose — as expected from the mechanism — unlike TRT where both fall.
• Sperm concentrations were maintained or improved, whereas men randomized to testosterone gel showed significant decreases in sperm concentration by week 16.
• Testicular volume was preserved in the enclomiphene arm; it declined in the testosterone gel arm.
• Symptom improvements — ADAM questionnaire (Androgen Deficiency in Aging Males), energy, libido scores — were comparable between enclomiphene and testosterone gel at 16 weeks. ^[4]

This is the core clinical case for enclomiphene: equivalent symptomatic benefit to TRT over the short study window, with preservation of the HPG axis and sperm production. The limitation is honest and worth stating: these trials ran 16 weeks, not years. Long-term HPG axis normalization — whether T levels remain stable on chronic enclomiphene or whether some degree of receptor downregulation occurs — is not fully characterized in multi-year data. ^[5]

HCG: LH-mimetic, Leydig cell signal, intratesticular testosterone

Human chorionic gonadotropin (HCG) is a glycoprotein hormone produced by the placental syncytiotrophoblast during pregnancy. Its clinical relevance in male endocrinology comes from its structural similarity to LH: both share the same alpha subunit and bind the same LH/HCG receptor (LHCGR) on testicular Leydig cells. HCG's beta subunit is structurally distinct from LH but binds LHCGR with higher affinity and a substantially longer half-life — approximately 24–36 hours versus LH's 20–30 minutes — making it a highly effective LH-mimetic for clinical purposes. ^[6]

When HCG binds LHCGR, it drives the same cAMP cascade as LH, stimulating Leydig cell testosterone synthesis. Crucially, it does this at the testicular level — meaning it does not require intact central HPG signaling. A man on exogenous testosterone whose LH is fully suppressed can still respond to HCG because the Leydig cells themselves are intact. HCG bypasses the silenced pituitary and speaks directly to the testes.

The key concept here is intratesticular testosterone (ITT — Intratesticular Testosterone). Serum testosterone — what you measure in a blood draw — is the fraction that has diffused out of the testes into systemic circulation. ITT, the testosterone concentration within the seminiferous tubules, is 50–100 times higher than serum testosterone and is the concentration that actually supports spermatogenesis. Exogenous TRT raises serum T but does not raise ITT — in fact, by suppressing LH and shutting down Leydig cell activity, it collapses ITT. ^[7]

HCG maintains ITT even when exogenous testosterone has suppressed endogenous LH. This is the pharmacological reason HCG is used alongside TRT in men who need to preserve fertility: the systemic testosterone signal is covered by the injection or gel, and HCG maintains the intra-testicular environment required for sperm production. Coviello et al. (2005) demonstrated this in a controlled study: men on testosterone alone showed a ~94% reduction in ITT; men on testosterone plus HCG (500 IU every other day) maintained ITT at or above baseline — actually approximately 126% of baseline — sufficient to preserve spermatogenesis in many subjects. ^[7]

The enclomiphene + HCG combination

Used together, enclomiphene and HCG hit the HPG axis from both ends. Enclomiphene works centrally — it removes E2-mediated negative feedback, allows GnRH pulsatility to increase, and drives endogenous LH and FSH secretion. HCG works peripherally — it directly stimulates the Leydig cells, maintaining ITT and testicular volume independent of the central signal.

The clinical rationale for combining them is specific: enclomiphene alone raises LH and FSH, but the actual testicular response to LH can be sluggish, especially in men who have been on TRT for extended periods and whose Leydig cells have become partially atrophied from chronic LH deprivation. Adding HCG provides a direct Leydig cell stimulus during the period when the endogenous LH response is recovering. FSH — which enclomiphene supports through the pituitary — drives Sertoli cell function and the spermatogenic process. The combination addresses both the testosterone production side (LH/HCG → Leydig) and the spermatogenesis support side (FSH → Sertoli). ^[8]

In clinical practice, a few protocol structures have coalesced around this combination, though these are not derived from published head-to-head combination trials — they are extrapolated from single-agent trial data and clinical experience:

• Enclomiphene 12.5–25 mg/day orally, titrated based on testosterone response and symptom burden. Some clinicians use 25 mg five days on / two days off to reduce side effects. (Dose planner → to map a titration schedule.)
• HCG 500–1,000 IU every other day (or 1,500 IU three times per week), subcutaneously. The every-other-day schedule approximates LH pulsatility more closely than once-weekly dosing.
• Labs at 6–8 weeks: total testosterone, free testosterone, LH, FSH, estradiol (sensitive assay), complete blood count (CBC — Complete Blood Count), and semen analysis if fertility is the primary goal.

Who benefits, who doesn't

The enclomiphene and HCG approach works in a specific subset of hypogonadal men. Getting the patient selection right is more important than getting the protocol right.

Strong candidates

Men with secondary hypogonadism — low or inappropriately normal LH alongside low testosterone — are the primary indication. The mechanism requires a functioning hypothalamus and pituitary (for enclomiphene) and intact Leydig cells (for HCG). If the axis can be stimulated, this approach can work. Causes of secondary hypogonadism include obesity-related HPG suppression, sleep apnea, hyperprolactinemia once treated, and functional hypogonadism in overweight men. ^[9]

Men transitioning off TRT who want to restore fertility are another strong candidate group. After stopping TRT, HPG axis recovery is not guaranteed and may take 4–24 months depending on duration of suppression. Enclomiphene + HCG is commonly used in this restart protocol to accelerate axis recovery and maintain ITT while the central axis reconnects. ^[10]

Young men (typically under 45) with symptomatic hypogonadism who have not yet completed fertility goals are perhaps the most important group: these are men who would otherwise be told to choose between treating their low T and preserving their ability to have children. The enclomiphene + HCG approach removes that forced choice for many of them.

Poor candidates

Men with primary hypogonadism — Klinefelter syndrome (47,XXY), testicular damage from trauma, chemotherapy, or radiation, or other forms of primary testicular failure — have intrinsically impaired Leydig cell function. HCG may still produce some testosterone rise, but the response will be attenuated and the fertility outlook is largely driven by the degree of testicular damage, not the protocol. These men typically need exogenous testosterone because the testes cannot respond adequately to upstream signaling.

Men with a pituitary adenoma or other structural HPG axis pathology need that pathology addressed first. Enclomiphene stimulating a broken axis is not useful and may mask the underlying problem.

Men who simply want higher-than-normal testosterone — who have normal baseline T but are seeking enhancement rather than treatment of true deficiency — are outside the clinical indication for any of these approaches. This is covered in the TRT article on this site. ^{[Related: TRT in 2026: FDA's New Libido Indication]}

Monitoring framework

A practical monitoring cadence for men on enclomiphene ± HCG, adapted from published clinical experience and the Endocrine Society's hypogonadism guideline framework: ^[9,11]

Baseline (before starting): Morning total testosterone (two measurements, at least one week apart), free testosterone, LH, FSH, prolactin (to rule out hyperprolactinemia), estradiol (sensitive assay), CBC (hematocrit — polycythemia risk applies to any testosterone-raising protocol), PSA (Prostate-Specific Antigen) in men over 40, fasting lipids, and semen analysis if fertility is the goal.

6–8 weeks: Total T, free T, LH, FSH, E2 (sensitive). Dose titration based on response. If using HCG, add a hematocrit check — testosterone-stimulating protocols carry polycythemia risk, though the risk appears lower than with direct TRT because the testosterone rise is more gradual. ^[12]

3–4 months: Full panel including CBC, PSA, lipids, and semen analysis if fertility tracking is needed. By this point, a responsive patient should show stabilized testosterone levels and a clear response signal.

Ongoing (every 6–12 months): Standard safety panel. If testosterone has stabilized and symptoms are controlled, the monitoring cadence can be stretched to annual with the treating physician's judgment.

When to escalate to TRT

Enclomiphene and HCG are not the right tool for every situation. If morning testosterone fails to reach a symptomatic response range after 3–4 months of optimized enclomiphene dosing, and the patient has completed fertility goals, moving to exogenous TRT is appropriate. If primary hypogonadism is the underlying diagnosis, TRT is typically first-line. If the patient's quality of life remains significantly impaired despite the HPG-stimulation approach, the conversation about direct testosterone replacement becomes straightforward.

The framework is: HPG-preserving approaches first, in men who are appropriate candidates, for as long as they are achieving therapeutic goals. TRT when the HPG-preserving approach is insufficient or inappropriate. These are not competing ideologies — they are tools with different indications.